When there’s too much that meets the eye, rest assured everything is taking place for a reason. As ChargePoint Technology sets up its office in India, there is a rapid movement that is bound to happen in the safe powder handling domain. ChargePoint, as we all know, has been mastering the patent technology in pharma containment and sterile powder transfer systems. They operate the industry-leading powder transfer systems that connect the process, thereby helping with secure and dependable product transfers.
The Indian pharmaceutical market is vast and dynamic and has been a disruptor as far as global standards are concerned. Coming up with a setup in India goes on to show ChargePoint’s thrust to enhance customer interaction and also put in place response times that are much faster, leading to a commitment to supporting the market. In this very exclusive interview session, we put forth the need for innovation and also prioritizing significant investment in research and development that have been the cornerstones of incredible outcomes. As the Indian pharmaceutical market estimates to mint $150 billion by the decade’s end, the opportunities for ChargePoint stand immense, which is what the backdrop of this very intriguing discussion is.
ChargePoint Technology World Pharma Today Q&A
1. Can you provide more details on what led to the decision to establish ChargePoint UK Private Ltd in India?
ChargePoint has cultivated strong relationships with our Indian customers over the past 15 years, and we deeply value these connections. The establishment of ChargePoint UK Private Ltd demonstrates our enduring commitment to the region. We recognize the necessity of a local presence to support operations effectively, ensuring rapid response times and readily available expertise. This latest venture has generated considerable excitement and energy throughout our organization.
Our goals in establishing a more proactive and visible presence in the Indian market include:
- Fostering deeper customer relationships through personalized outreach, enhanced education and increased awareness.
- Providing targeted support, including one-to-one technical seminars, lunch-and-learn sessions and participation in industry events such as the Pharmaceutical Machinery and Equipment Convention (PMEC) India.
- Enhancing our profile, showcasing the full breadth of our capabilities and solutions.
- Improving customer support by offering greater proximity and faster response times for service and in-person assistance.
- Identifying and creating new opportunities for both our customers and ourselves.
Our focus on future growth is driven by the current size and strength of the Indian market, as well as its promising future infrastructure. This is reflected in India’s pharmaceutical industry, currently worth $50 billion and projected to reach $130 billion by 2030[1]. India is a major exporter of pharmaceuticals, fulfilling a significant portion of global generic drug demand. The country is also a dominant force in vaccine production, supplying around 60% of global demand[2].
A number of drivers are behind the rapid growth of the Indian pharmaceutical industry. India has the highest number of US-FDA-compliant plants outside the US, and it has strong manufacturing expertise in low-cost generic patented drugs, as well as end-to-end production. Government incentives called Production Linked Incentives are encouraging companies to onshore the supply of drug active components to ensure India’s drug security.
2. How does ChargePoint’s new subsidiary aim to address the specific needs of the Indian pharmaceutical market?
An increased local presence offers several advantages for our clients. It allows us to enhance customer communication, enabling more frequent and personalized interactions. Additionally, it leads to a deeper understanding of the local market, including customer needs, preferences and business practices. With a local presence, we can achieve faster response times to support requests and project inquiries. It also ensures cultural sensitivity and a nuanced understanding of the local business environment. By establishing a local presence, we demonstrate our commitment to the Indian market, thereby strengthening customer relationships. Finally, our technologies can assist customers and manufacturers in navigating evolving regulations and maintaining drug product quality and safety, further supporting our commitment to the market.
3. What are the key strategic goals for ChargePoint UK Private Ltd over the next five years?
Our goals for ChargePoint UK Private Ltd over the next five years are to:
- Expand our customer base
- Increase our market presence
- Create new business opportunities.
We aim to be the top Indian partner and supplier for aseptic processing and containment needs. We’re committed to deepening and expanding our existing customer relationships while broadening our customer contact and service. To achieve this, we will continue building on our dedicated support team to handle new projects, service requests and customer relationships.
4. What are the major challenges you see in the Indian pharmaceutical manufacturing sector and how is ChargePoint equipped to address them?
There is a growing demand for higher containment and aseptic control within the Indian pharmaceutical market. This trend is driven by several factors, including:
- Stringent regulatory requirements: Regulatory bodies in India are aligning their guidelines with international standards, meaning pharmaceutical manufacturers must adopt increasingly stringent measures for contamination control and aseptic processing to ensure product quality and safety.
- Rising focus on sterile products: The Indian pharmaceutical industry is seeing more demand for the production of sterile injectables, biopharmaceuticals and other high-value products. These products require meticulous aseptic processing techniques to prevent microbial contamination and ensure patient safety.
- Market competition: The Indian pharmaceutical market is highly competitive, with both domestic and international players vying for market share. To maintain a competitive edge, manufacturers are investing in state-of-the-art facilities and adopting best practices in containment and aseptic processing.
ChargePoint is continuously developing state-of-the-art solutions to address these demands and challenges within the Indian market with a strong focus on future
With the Indian pharmaceutical industry expected to reach $150 billion approx by 2030, what growth opportunities do you foresee for ChargePoint in this market?
Innovations that address the increasingly complex needs of the industry are in high demand. By actively listening to the needs and requirements of our customers, we can develop innovative solutions that effectively meet and exceed their expectations.
5. How does ChargePoint plan to stay ahead of the competition in the rapidly growing Indian market?
We have a keen focus on innovation, prioritizing significant investment in research and development. This is evident in our state-of-the-art solutions and advanced manufacturing processes.
Our team of highly experienced experts, strategically located in key Indian pharmaceutical hubs, is dedicated to educating our customers on product innovations and new launches,. They also help customers understand and adapt to evolving GMP regulations. This proactive approach ensures that both we and our customers maintain a competitive edge.
6. How does the expansion into India fit into ChargePoint’s overall global strategy?
As a business, ChargePoint is continuously working towards expanding and reinforcing our global presence. Global growth is a key element of our overall strategy and we have identified India as a significant growth opportunity. Backed by our extensive expertise and in-depth knowledge, we are well-placed to capitalize on this market and further strengthen our international presence.
7. How do you plan to engage with local customers and gather feedback to continuously improve your products and services?
Our new team of dedicated and experienced specialists in India is here to deliver exceptional customer support, exceeding expectations through regular health checks, equipment inspections and on-site training. By actively listening to customer challenges, we ensure tailored solutions that truly meet their needs. Our team, encompassing Business Development, Technical Service and AfterCare, guarantees comprehensive support throughout the entire installation lifecycle and beyond, supporting ongoing maintenance.
8. Can you share some success stories or case studies from your existing Indian customers?
Not at this time due to customer company confidentiality
9. What are some of the innovative solutions ChargePoint is developing or has recently introduced to the market?
ChargePoint maintains its industry leadership by anticipating and adapting to the evolving needs of our customers. We achieve this through active engagement with our market, continuous research and development, and a commitment to agility. Our recent innovations include:
- Broadening our flexible packaging chargebag product line to include a wider range of volumes and sizes (2D and 3D) to support even more customers with a broader array of batch size needs.
- Introducing innovative robotic material handling solutions aligned to our PuroVaso product line designed to improve efficiency for pharma manufacturers looking to automate and update their production processes and meet future demand for delivering life-saving drug products to market.
In addition to adding new solutions to our product portfolio, we have also opened a new cleanroom facility to help us meet growing global customer demand while streamlining turnaround times for orders. These efforts enable us to consistently meet and exceed customer expectations while driving ongoing growth and improvement.
10. What role does innovation play in ChargePoint’s strategy, and can you share any upcoming innovations or projects?
Our commitment to continuous product innovation is a driving force behind our success. As innovation is a core component of our company strategy, we are able to meet growing market demands. Key examples of our innovation focus include:
- Powder transfer : We are investing in advanced robotics solutions that will support the customers move into semi continuous process lines which in turn will improve customer efficiency and productivity.
- Flexible packaging : We are continuing to introduce and develop new single-use bag products to address specific market needs, helping deliver the efficiency benefits of single-use technology to a wider range of companies.
- Fluid management : Our acquisition of the Terracon product line in 2023 means we can expand our fluid management capabilities and solutions. This includes exploring new solutions to support customers in meeting their unique fluid management needs.
Reference:
1. https://www.ibef.org/industry/pharmaceutical-india
2. https://www.investindia.gov.in/team-india-blogs/indias-vaccine-manufacturing prowess#:~:text=India%20now%20supplies%20~60%25%20of,of%20India’s%20pharmaceuticals’%20export%20portfolio.
